Association of diabetes mellitus with prostate cancer: Nested case-control study (Prostate testing for cancer and Treatment study)

International Journal of Cancer

Volumn 128, Issue 2, 2011, Pages 440-446

  Turner, Emma L ^a   Lane, Janet Athene ^a   Donovan, Jenny L ^a   Davis, Michael J ^a   Metcalfe, Chris ^a   Neal, David E ^b   Hamdy, Freddie C ^c   Martin, Richard M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

case control study; diabetes; prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; QUESTIONNAIRE; RISK REDUCTION;

AGED; BODY MASS INDEX; CASE-CONTROL STUDIES; DIABETES MELLITUS; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 78649601393     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25360     Document Type: Article

References (41)

1. Parkin DM, Bray FI, Devesa SS,. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37: 4-66.
2. Gronberg H,. Prostate cancer epidemiology. Lancet 2003; 361: 859-64.
3. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K,. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78-85.
4. Frankel S, Davey Smith G, Donovan J, Neal D,. Screening for prostate cancer. Lancet 2003; 361: 1122-8.
5. World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: AICR, 2007.
6. Kasper JS, Giovannucci E,. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 2056-62.
7. Bonovas S, Filioussi K, Tsantes A,. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 2004; 47: 1071-8.
8. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenex M, Downs J,. The prostate specific antigen era in the United States is over for prostate cancer: what has happened in the last 20 years. J Urol 2004; 172: 1297-301.
9. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC,. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 2007; 121: 1571-8.
10. Giovannucci E,. Does prostate-specific antigen screening influence the results of studies of tomatoes, lycopene, and prostate cancer risk? J Natl Cancer Inst 2007; 99: 1060-2.
11. Hsing AW, Sakoda LC, Chua SC, Jr,. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 2007; 86: 843S-857S.
12. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE,. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 2005; 161: 147-52.
13. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC,. Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes Control 1998; 9: 3-9. (Pubitemid 28048654)
14. Calton B, Chang S, Wright M, Kipnis V, Lawson K, Thompson F, Subar A, Mouw T, Campbell D, Hurwitz P, Hollenbeck A, Schatzkin A, et al. History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP Diet and Health Study. Cancer Causes Control 2007; 18: 493-503. (Pubitemid 46684823)
15. Tavani A, Gallus S, Bosetti C, Tzonou A, Lagiou P, Negri E, Trichopoulos D, La Vecchia C,. Diabetes and the risk of prostate cancer. Eur J Cancer Prev 2002; 11: 125-8.
16. Larsson SC, Orsini N, Wolk A,. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005; 97: 1679-87.
17. Giovannucci E,. Medical history and etiology of prostate cancer. Epidemiol Rev 2001; 23: 159-62.
18. Renehan AG, Zwahlen M, Minder PC, O'Dwyer ST, Shalet PS, Egger PM,. Insulin-like growth factor (IGF)-I. IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004; 363: 1346-53.
19. Barnard RJ, Aronson WJ, Tymchuk CN, Ngo TH,. Prostate cancer: another aspect of the insulin-resistance syndrome? Obes Rev 2002; 3: 303-8.
20. Donovan J, Mills N, Smith M, Brindle L, Jacoby A, Peters T, Frankel S, Neal D, Hamdy F, Little P,. Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. BMJ 2002; 325: 766-70.
21. Platz EA, De Marzo AM, Giovannucci E,. Prostate cancer association studies: pitfalls and solutions to cancer misclassification in the PSA era. J Cell Biochem 2004; 91: 553-71.
22. Donovan JL, Hamdy FC, Neal DE, Peters TJ, Oliver S, Brindle L, Jewell D, Powell P, Gillatt D, Dedman D, Mills N, Smith M, et al. Prostate testing for cancer and Treatment (ProtecT) feasibility study. Health Technol Assess 2003; 7: 1-42.
23. Oliver SE, Gunnell D, Donovan J, Peters TJ, Persad R, Gillatt D, Pearce A, Neal DE, Hamdy FC, Holly J,. Screen-detected prostate cancer and the insulin-like growth factor axis: results of a population-based case-control study. Int J Cancer 2004; 108: 887-92.
24. Ohori M, Wheeler TM, Scardino PT,. The new American Joint Committee on Cancer and International Union against Cancer TNM classification of prostate cancer. Cancer 1994; 73: 104-14.
25. Barker DJ, Gardner MJ, Power C,. Incidence of diabetes amongst people aged 18-50 years in nine British towns: a collaborative study. Diabetologia 1982; 22: 421-5.
26. Godin G, Shephard RJ,. A simple method to assess exercise behavior in the community. Can J Appl Sport Sci 1985; 10: 141-6.
27. Werny DM, Saraiya M, Gregg EW,. Prostate-specific antigen values in diabetic and nondiabetic US men, 2001-2002. Am J Epidemiol 2006; 164: 978-83.
28. Rose D, O'Reilly K,. The ESRC review of Government Social Classifications. London: Economic and Social Research Council and the Government Statistical Service, 1998.
29. Zhu K, Lee IM, Sesso HD, Buring JE, Levine RS, Gaziano JM,. History of diabetes mellitus and risk of prostate cancer in physicians. Am J Epidemiol 2004; 159: 978-82.
30. Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, Lippman SM, Platz EA, Pollak MN, Thompson IM, Kristal AR,. Obesity, diabetes and risk of prostate cancer: results from the prostate cancer prevention trial cancer. Epidemiol Biomarkers Prev 2006; 15: 1977-83.
31. Banez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, Wang Y, Terris MK, Aronson WJ, Presti JC, Jr, Kane CJ, Amling CL, et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. J Am Med Assoc 2007; 298: 2275-80.
32. Chan JM, Latini DM, Cowan J, Duchane J, Carroll PR,. History of diabetes, clinical features of Prostate cancer, and prostate cancer recurrence-data from CaPSURETM (United States). Cancer Causes Control 2005; 16: 789-97.
33. Giovannucci E, Michaud D,. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007; 132: 2208-25.
34. Hammarsten J, Hogstedt B,. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005; 41: 2887-95.
35. Bell GI, Polonsky KS,. Diabetes mellitus and genetically programmed defects in beta-cell function. Nature 2001; 414: 788-91.
36. Velicer CM, Dublin S, White E,. Diabetes and the risk of prostate cancer: the role of diabetes treatment and complications. Prostate Cancer Prostatic Dis 2006; 10: 46-51.
37. Gonzalez-Perez A, Garcia Rodriguez LA,. Prostate cancer risk among men with diabetes mellitus (Spain). Cancer Causes Control 2005; 16: 1055-8.
38. Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, Manolescu A, Rafnar T, Gudbjartsson D, Agnarsson BA, Baker A, Sigurdsson A, Benediktsdottir KR, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007; 39: 977-83.
39. Agalliu I, Suuriniemi M, Prokunina-Olsson L, Johanneson B, Collins FS, Stanford JL, Ostrander EA,. Evaluation of a variant in the transcription factor 7-like 2 (TCF7L2) gene and prostate cancer risk in a population-based study. Prostate 2008; 68: 740-7.
40. Freedland SJ, Platz EA,. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 2007; 29: 88-97.
41. Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ,. Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol 2004; 57: 1096-103.